Taking 250 mg of magnesium and 250 mg of potassium daily for two months improves sleep quality and reduces insomnia in people with diabetes by increasing melatonin and lowering cortisol, two key hormones that regulate sleep.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of multiple double-blind RCTs across diverse diabetic populations would establish whether magnesium and potassium supplementation consistently improves insomnia severity and sleep hormone levels, accounting for dosage, duration, and comorbidities.
A systematic review and meta-analysis of all double-blind, placebo-controlled RCTs evaluating magnesium (150–500 mg/day) and potassium (100–300 mg/day) supplementation in adults with type 2 diabetes and clinically diagnosed insomnia, measuring ISI scores, serum melatonin, and cortisol before and after 4–12 weeks of treatment, with standardized outcome definitions and adjustment for HbA1c, BMI, and depression scores.
A double-blind RCT with adequate power would confirm whether the observed improvements in sleep hormones and ISI are directly caused by supplementation, independent of placebo effects or unmeasured confounders.
A double-blind, placebo-controlled RCT with 500 participants aged 30–70 with type 2 diabetes and moderate-to-severe insomnia (ISI ≥15), randomized to receive 250 mg magnesium gluconate + 250 mg potassium chloride, either supplement alone, or placebo daily for 8 weeks, with primary outcomes being change in ISI score, serum melatonin, and cortisol, and secondary outcomes including sleep efficiency via actigraphy and HbA1c, while screening for depression and anxiety at baseline.
A prospective cohort study would determine whether long-term magnesium and potassium intake predicts sustained improvements in sleep quality and hormone levels in diabetic populations over years.
A prospective cohort study following 1,000 adults with type 2 diabetes for 3 years, measuring dietary magnesium and potassium intake via food diaries and serum levels quarterly, and assessing ISI scores and sleep hormone concentrations annually, while controlling for medication use, sleep hygiene, and mental health status.
A case-control study would compare magnesium and potassium levels in diabetic patients with severe insomnia versus those with normal sleep to identify whether deficiency is more common in those with poor sleep.
A case-control study comparing serum magnesium and potassium levels in 200 diabetic patients with severe insomnia (ISI ≥22) and 200 diabetic patients with normal sleep (ISI ≤7), matched for age, sex, HbA1c, and medication use, with blood drawn under standardized fasting conditions.
A cross-sectional study would identify whether lower serum magnesium or potassium levels are associated with higher ISI scores in diabetic patients at a single time point.
A cross-sectional survey of 1,000 diabetic patients measuring serum magnesium, potassium, melatonin, cortisol, and ISI scores in a single visit, with adjustment for age, sex, BMI, and diabetes duration.